Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new platform release. The change does not alter the study details or visible content on the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page displays Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer build of the page's interface without changes to the study information.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page’s displayed software release/revision indicator was updated from v3.5.2 to v3.5.3, reflecting a website version change rather than any modification to the study record.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No visible content or functionality changes.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision tag updated to v3.5.0, replacing the previous v3.4.3. No study content or results are impacted.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.